Giovanni Barosi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6394841/publications.pdf

Version: 2024-02-01

171	16,421	23567 58	15732 125
papers	citations	h-index	g-index

173	173	173	8835
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	27.0	1,543
2	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	1.4	1,110
3	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	1.4	808
4	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
5	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
6	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	1.4	383
7	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	1.6	373
8	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	1.6	344
9	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica, 2007, 92, 95-100.	3.5	341
10	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	1.4	340
11	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108, 1497-1503.	1.4	317
12	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007, 31, 737-740.	0.8	288
13	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	1.4	286
14	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	1.4	280
15	Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44, 1528-1534.	7.3	249
16	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	1.4	242
17	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	1.4	233
18	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	1.4	229

#	Article	IF	Citations
19	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	1.4	219
20	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	1.4	216
21	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	1.4	216
22	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	1.6	213
23	Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines. Journal of Clinical Oncology, 1999, 17, 2954-2954.	1.6	208
24	A pilot study of the Histoneâ€Ðeacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 2010, 150, 446-455.	2.5	202
25	Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2004, 89, 215-32.	3.5	199
26	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood, 2001, 98, 3249-3255.	1.4	197
27	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	1.4	196
28	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 2005, 105, 4115-4119.	1.4	194
29	Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood, 2007, 110, 986-993.	1.4	186
30	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 1999, 104, 730-737.	2.5	179
31	Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 1998, 102, 684-690.	2.5	168
32	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	4.1	165
33	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	3.5	160
34	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	2.5	153
35	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145
36	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144

#	Article	IF	Citations
37	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	1.4	144
38	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
39	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. Journal of Clinical Oncology, 2004, 22, 424-431.	1.6	134
40	A prognostic classification of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 1988, 70, 397-401.	2.5	115
41	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	3.2	111
42	A phase II study of <scp>G</scp>ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology, 2013, 161, 688-694.	2.5	109
43	Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood, 2005, 105, 4508-4515.	1.4	106
44	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	1.4	105
45	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Advances, 2019, 3, 1729-1737.	5.2	105
46	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	1.4	102
47	Chronic Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2003, 2003, 200-224.	2.5	101
48	Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	3.2	91
49	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. Leukemia and Lymphoma, 2002, 43, 2301-2307.	1.3	90
50	Characterization of the TGF-Î²1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood, 2013, 121, 3345-3363.	1.4	86
51	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2001, 114, 78-83.	2.5	85
52	Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. PLoS ONE, 2012, 7, e35631.	2.5	85
53	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2â€“Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. Journal of Clinical Oncology, 2005, 23, 5688-5695.	1.6	81
54	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood, 2009, 114, 3127-3130.	1.4	79

#	Article	IF	Citations
55	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	1.4	75
56	An Immune Dysregulation in MPN. Current Hematologic Malignancy Reports, 2014, 9, 331-339.	2.3	75
57	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica, 2009, 94, 550-565.	3.5	66
58	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	1.4	60
59	Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis. PLoS ONE, 2014, 9, e91099.	2.5	60
60	The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood, 2005, 105, 1699-1705.	1.4	58
61	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 2010, 116, 1051-1055.	1.4	56
62	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
63	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 324-329.	2.0	56
64	New and Old Treatment Modalities in Primary Myelofibrosis. Cancer Journal (Sudbury, Mass), 2007, 13, 377-383.	2.0	53
65	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	1.4	52
66	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	1.4	52
67	Thrombopoietin/TGF-Î²1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. Stem Cells, 2016, 34, 1123-1133.	3.2	49
68	In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes. PLoS ONE, 2011, 6, e21015.	2.5	48
69	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	3.5	48
70	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	2.8	47
71	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	1.4	47
72	Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. Experimental Hematology, 2015, 43, 1019-1030.e3.	0.4	46

#	Article	IF	Citations
73	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
74	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2004, 124, 618-625.	2.5	43
75	Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter. Best Practice and Research in Clinical Haematology, 2014, 27, 129-140.	1.7	43
76	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
77	Deciding when to intervene: a Markov decision process approach. International Journal of Medical Informatics, 2000, 60, 237-253.	3.3	40
78	Myelofibrosis with myeloid metaplasia. Hematology/Oncology Clinics of North America, 2003, 17, 1211-1226.	2.2	35
79	Idiopathic Myelofibrosis. Seminars in Hematology, 2005, 42, 248-258.	3.4	35
80	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	3.5	35
81	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	5.7	35
82	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. American Journal of Clinical Pathology, 2006, 126, 241-247.	0.7	34
83	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1991, 68, 2310-2318.	4.1	33
84	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood, 2012, 120, 3112-3117.	1.4	33
85	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	4.1	33
86	<scp>SIE</scp>, <scp>SIES</scp>, <scp>GITMO</scp> revised guidelines for the management of follicular lymphoma. American Journal of Hematology, 2013, 88, 185-192.	4.1	32
87	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 75-85.	0.4	32
88	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 1662-73.	3.5	32
89	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. Best Practice and Research in Clinical Haematology, 2006, 19, 495-517.	1.7	31
90	Activation of non-canonical TGF-Î²1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells, Molecules, and Diseases, 2015, 54, 234-241.	1.4	31

#	Article	IF	Citations
91	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood, 2008, 111, 4418-4418.	1.4	30
92	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	2.5	30
93	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	7.2	30
94	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica, 2005, 90, 1236-57.	3.5	30
95	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 96-103.	3.5	30
96	Evaluation of the bioactive and total transforming growth factor Î²1 levels in primary myelofibrosis. Cytokine, 2011, 53, 100-106.	3.2	29
97	Involvement of TGFÂ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica, 2013, 98, 514-517.	3.5	29
98	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology, 2012, 91, 875-888.	1.8	28
99	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.8	28
100	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia Research, 2017, 60, 18-23.	0.8	27
101	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. European Journal of Haematology, 2001, 66, 324-327.	2.2	26
102	Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. British Journal of Haematology, 1996, 92, 150-154.	2.5	25
103	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	1.8	25
104	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.8	25
105	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget, 2017, 8, 54082-54095.	1.8	25
106	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	6.2	25
107	Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. Seminars in Oncology, 2005, 32, 395-402.	2.2	23
108	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2009, 94, 102-112.	3.5	23

#	Article	IF	Citations
109	Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice. Current Hematologic Malignancy Reports, 2012, 7, 50-56.	2.3	19
110	Role of TGF â€î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	4.6	19
111	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	4.1	18
112	Altered fibronectin expression and deposition by myeloproliferative neoplasmâ€derived mesenchymal stromal cells. British Journal of Haematology, 2016, 172, 140-144.	2.5	18
113	Studies of the Site and Distribution of CD34+ Cells in Idiopathic Myelofibrosis. American Journal of Clinical Pathology, 2005, 123, 833-839.	0.7	17
114	JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leukemia Research, 2012, 36, e7-e9.	0.8	17
115	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets and Therapy, 2015, 8, 1091.	2.0	17
116	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. American Journal of Pathology, 2017, 187, 1879-1892.	3.8	17
117	Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. Leukemia Research, 2010, 34, 1119-1120.	0.8	16
118	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	3.5	15
119	Is there expert consensus on expert consensus?. Bone Marrow Transplantation, 2018, 53, 1055-1060.	2.4	15
120	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood, 2013, 122, 4070-4070.	1.4	15
121	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. PLoS ONE, 2013, 8, e59791.	2.5	15
122	From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology American Society of Hematology Education Program, 2008, 2008, 83-91.	2.5	13
123	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 2014, 38, 1269-1277.	0.8	13
124	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 507-513.	0.4	13
125	Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood, 2016, 128, 1660-1662.	1.4	13
126	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	1.8	13

#	Article	IF	Citations
127	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2019, 25, 855-860.	2.0	13
128	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. American Journal of Clinical Pathology, 2006, 126, 241-247.	0.7	13
129	Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood Advances, 2022, 6, 2331-2333.	5.2	13
130	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	1.4	12
131	Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity. Cancer, 1983, 52, 1290-1296.	4.1	11
132	Novel strategies for patients with chronic myeloproliferative disorders. Current Opinion in Hematology, 2009, 16, 129-134.	2.5	11
133	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia Research, 2019, 81, 88-94.	0.8	11
134	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Current Opinion in Hematology, 2006, 13, 74-78.	2.5	10
135	CD14brightCD16low intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Experimental Hematology, 2014, 42, 244-246.	0.4	9
136	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in nonâ€Hodgkin lymphoma: a <scp>SIE</scp>,<scp> SIES</scp>, and <scp>GITMO</scp> consensus paper. European Journal of Haematology, 2016, 97, 554-561.	2.2	9
137	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	7.2	9
138	Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers, 2021, 13, 2552.	3.7	9
139	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. American Journal of Hematology, 2018, 93, 615-622.	4.1	8
140	Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. Leukemia, 2019, 33, 588-596.	7.2	8
141	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
142	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research, 2012, 36, 459-466.	0.8	7
143	Plasma sIL-2RÎ± levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leukemia Research, 2020, 90, 106319.	0.8	7
144	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	7.2	7

#	Article	IF	Citations
145	Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. Critical Reviews in Oncology/Hematology, 2022, 172, 103623.	4.4	7
146	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPNâ€associated myelofibrosis. American Journal of Hematology, 2016, 91, 709-713.	4.1	6
147	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood, 2012, 120, 804-804.	1.4	6
148	New Markers of Disease Progression in Myelofibrosis. Cancers, 2021, 13, 5324.	3.7	6
149	Consensus conference on the use of 90â€yttriumâ€ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology, 2010, 85, 147-155.	4.1	5
150	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. Haematologica, 2002, 87, 472-8.	3.5	5
151	Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: Deconstructing a myth?. Leukemia Research, 2011, 35, 563-565.	0.8	4
152	Emerging targeted therapies in myelofibrosis. Expert Review of Hematology, 2012, 5, 313-324.	2.2	4
153	No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. Haematologica, 2013, 98, e83-e84.	3.5	4
154	COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021034.	1.3	4
155	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	2.4	4
156	Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34⁺ haematopoietic progenitor cells in primary myelofibrosis. British Journal of Haematology, 2011, 152, 665-667.	2.5	3
157	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 2019, 14, e0220189.	2.5	3
158	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS ONE, 2016, 11, e0156990.	2.5	3
159	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. Leukemia Research, 2021, 111, 106730.	0.8	3
160	New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia. European Journal of Haematology, 2007, 79, 24-26.	2.2	2
161	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	7.2	2
162	Transplant indications, guidelines and recommendations: Caveat Emptor. Bone Marrow Transplantation, 2022, 57, 149-151.	2.4	2

#	Article	IF	Citations
163	Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis. Current Hematologic Malignancy Reports, 2015, 10, 362-369.	2.3	1
164	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. Blood, 2014, 124, 3192-3192.	1.4	1
165	Management of Myelofibrosis. , 2007, , 125-142.		1
166	Conventional and Investigational Therapy for Primary Myelofibrosis. , 2011, , 117-138.		1
167	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	1.4	1
168	Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. Clinical Investigation, 2015, 5, 643-651.	0.0	0
169	Response to the Commentary on â€œIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myelomaâ€• Leukemia, 2019, 33, 1301-1302.	7.2	0
170	Current Clinical Needs. , 2012, , 149-161.		0
171	Everyone is entitled to his or her own opinion but not to their own facts*. British Journal of Haematology, 2022, 196, 1290-1292.	2.5	0